Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Pollard JA"" wg kryterium: Autor


Tytuł:
Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy.
Autorzy:
Leger KJ; Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA, United States.
Robison N; Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA, United States.
Narayan HK; Division of Cardiology, Department of Pediatrics, Rady Children's Hospital San Diego, University of California San Diego, La Jolla, CA, United States.
Smith AM; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Tsega T; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Chung J; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Daniels A; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Chen Z; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Englefield V; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Demissei BG; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Lefebvre B; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Morrow G; Division of Cardiology, Children's Healthcare of Atlanta, Atlanta, GA, United States.
Dizon I; Division of Cardiology, Seattle Children's Hospital, Seattle, WA, United States.
Gerbing RB; Children's Oncology Group, Monrovia, CA, United States.
Pabari R; Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Getz KD; Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Aplenc R; Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Pollard JA; Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Department of Pediatrics, Harvard Medical School, Boston, MA, United States.
Chow EJ; Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA, United States.; Clinical Research and Public Health Sciences Divisions, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Tang WHW; Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, United States.
Border WL; Division of Cardiology, Children's Healthcare of Atlanta, Atlanta, GA, United States.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.
Sachdeva R; Division of Cardiology, Children's Healthcare of Atlanta, Atlanta, GA, United States.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.
Alonzo TA; Children's Oncology Group, Monrovia, CA, United States.; Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Kolb EA; Nemours Center for Cancer and Blood Disorders, Alfred I. DuPont Hospital for Children, Wilmington, DE, United States.
Cooper TM; Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA, United States.
Ky B; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Pokaż więcej
Źródło:
Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2023 Dec 01; Vol. 10, pp. 1286241. Date of Electronic Publication: 2023 Dec 01 (Print Publication: 2023).
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.
Autorzy:
Cooper TM; Department of Pediatrics, Seattle Children's Hospital Cancer and Blood Disorders Service, University of Washington School of Medicine, Seattle, Washington, USA.
Alonzo TA; Department of Population and Public Health Sciences, University of Southern California, Los Angels, California, USA.
Tasian SK; Department of Pediatrics, Children's Hospital of Philadelphia Division of Oncology and Center for Childhood Cancer Research and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Kutny MA; Department of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Hitzler J; Division of Hematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada.; Department of pediatrics, Developmental and Stem Cell Biology, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Pollard JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of pediatrics, Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
Aplenc R; Department of Pediatrics, Children's Hospital of Philadelphia Division of Oncology and Center for Childhood Cancer Research and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Meshinchi S; Department of Pediatrics, Seattle Children's Hospital Cancer and Blood Disorders Service, University of Washington School of Medicine, Seattle, Washington, USA.; University of Washington, Department of Pediatrics, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Kolb EA; Department of Pediatrics, Nemours Center for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, Delaware, USA.
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2023 Sep; Vol. 70 Suppl 6, pp. e30584. Date of Electronic Publication: 2023 Jul 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Antineoplastic Agents*/therapeutic use
Hematopoietic Stem Cell Transplantation*
Humans ; Child ; Prognosis ; Sorafenib/therapeutic use ; Gemtuzumab/therapeutic use ; Mutation ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł:
Impact of cytoreduction and remission status on hematopoietic cell transplantation outcomes in pediatric myelodysplastic syndrome and related disorders.
Autorzy:
Wachter F; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Hebert K; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Pikman Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Yang J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Shah B; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Bledsoe J; Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Shimamura A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Neuberg DS; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Pollard JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Lehmann LE; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2023 Jun 27, pp. e30530. Date of Electronic Publication: 2023 Jun 27.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy.
Autorzy:
Tarlock K; Seattle Children's Hospital, Division of Hematology/Oncology, and University of Washington Seattle, Washington; Fred Hutchinson Cancer Research Center, Clinical Research Division and University of Washington, Seattle, Washington. Electronic address: .
Sulis ML; Department of Pediatric Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Chewning JH; Department of Pediatrics Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Pollard JA; Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
Cooper T; Seattle Children's Hospital, Division of Hematology/Oncology, and University of Washington Seattle, Washington.
Gamis A; Division of Hematology/Oncology, Children's Mercy Hospital and Clinics, Kansas City, Missouri.
Shenoy S; Division of Pediatric Hematology/Oncology, Washington University in St. Louis, St. Louis, Missouri.
Kutny M; Department of Pediatrics Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Horan J; Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
Meshinchi S; Fred Hutchinson Cancer Research Center, Clinical Research Division and University of Washington, Seattle, Washington.
Boelens JJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Bleakley M; Fred Hutchinson Cancer Research Center, Clinical Research Division and University of Washington, Seattle, Washington.
Carpenter PA; Fred Hutchinson Cancer Research Center, Clinical Research Division and University of Washington, Seattle, Washington.
Kolb EA; Nemours Center for Cancer and Blood Disorders, Alfred I. DuPont Hospital for Children, Wilmington, Delaware.
Pokaż więcej
Źródło:
Transplantation and cellular therapy [Transplant Cell Ther] 2022 Sep; Vol. 28 (9), pp. 530-545. Date of Electronic Publication: 2022 Jun 16.
Typ publikacji:
Practice Guideline; Review
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*
Myelodysplastic Syndromes*
Child ; Humans ; Recurrence ; Transplantation Conditioning ; Transplantation, Homologous ; United States
Recenzja
Tytuł:
Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group.
Autorzy:
Elgarten CW; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Wood AC; University of Auckland, Auckland, New Zealand.
Li Y; Department of Biostatistics, Epidemiology, and Informatics, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Alonzo TA; University of Southern California, Los Angeles, California, USA.
Brodersen LE; Hematologics, Inc., Seattle, Washington, USA.
Gerbing RB; Children's Oncology Group, Monrovia, California, USA.
Getz KD; Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Biostatistics, Epidemiology, and Informatics, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Huang YV; Department of Biomedical Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Loken M; Hematologics, Inc., Seattle, Washington, USA.
Meshinchi S; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Pollard JA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Boston Children's Hospital, Boston, Massachusetts, USA.
Sung L; The Hospital for Sick Children, Toronto, Ontario, Canada.
Woods WG; Aflac Cancer and Blood Disorders Center, Emory University/Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Kolb EA; Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA.
Gamis AS; Children's Mercy Hospital and Clinics, Kansas City, Missouri, USA.
Aplenc R; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Biostatistics, Epidemiology, and Informatics, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2021 Dec; Vol. 68 (12), pp. e29281. Date of Electronic Publication: 2021 Oct 01.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Induction Chemotherapy*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/etiology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Busulfan/therapeutic use ; Child ; Clinical Trials as Topic ; Cytarabine/therapeutic use ; Disease-Free Survival ; Humans ; Neoplasm, Residual/drug therapy ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Harmonising topographic & remotely sensed datasets, a reference dataset for shoreline and beach change analysis.
Autorzy:
Pollard JA; Coastal Research Unit, Department of Geography, University of Cambridge, Downing Place, Cambridge, CB2 3EN, UK. .
Brooks SM; Department of Geography, Birkbeck, University of London, Malet Street, London, WC1E 7HX, UK.
Spencer T; Coastal Research Unit, Department of Geography, University of Cambridge, Downing Place, Cambridge, CB2 3EN, UK.
Pokaż więcej
Źródło:
Scientific data [Sci Data] 2019 Apr 26; Vol. 6 (1), pp. 42. Date of Electronic Publication: 2019 Apr 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł:
Lightning Rods, Earthquakes, and Regional Identities: Towards a Multi-Scale Framework of Assessing Fracking Risk Perception.
Autorzy:
Pollard JA; Department of Geography, University of Cambridge, Cambridge, UK.
Rose DC; Department of Geography, University of Cambridge, Cambridge, UK.; School of Environmental Sciences, University of East Anglia, Norwich, UK.
Pokaż więcej
Źródło:
Risk analysis : an official publication of the Society for Risk Analysis [Risk Anal] 2019 Feb; Vol. 39 (2), pp. 473-487. Date of Electronic Publication: 2018 Aug 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Earthquakes*
Hydraulic Fracking*
Lightning*
Risk Assessment/*methods
Environmental Monitoring/methods ; Humans ; Mass Media ; Natural Gas ; New Zealand ; Prospective Studies ; Public Opinion ; Reproducibility of Results
Czasopismo naukowe
Tytuł:
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Autorzy:
Tarlock K; Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Hematology and Oncology, Seattle Children's Hospital, Seattle, Washington.
Chang B
Cooper T
Gross T
Gupta S
Neudorf S
Adlard K
Ho PA
McGoldrick S
Watt T
Templeman T
Sisler I
Garee A
Thomson B
Woolfrey A
Estey E
Meshinchi S
Pollard JA
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2015 Jun; Vol. 62 (6), pp. 1048-54. Date of Electronic Publication: 2015 Feb 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Tandem Repeat Sequences*
Antineoplastic Agents/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Niacinamide/*analogs & derivatives
Phenylurea Compounds/*therapeutic use
fms-Like Tyrosine Kinase 3/*genetics
Adolescent ; Adult ; Child ; Graft vs Host Disease/etiology ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/therapy ; Neoplasm, Residual ; Niacinamide/adverse effects ; Niacinamide/therapeutic use ; Phenylurea Compounds/adverse effects ; Retrospective Studies ; Sorafenib
Czasopismo naukowe
Tytuł:
Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.
Autorzy:
Walter RB; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA [3] Department of Epidemiology, University of Washington, Seattle, WA, USA.
Laszlo GS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Lionberger JM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Pollard JA; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Department of Pediatrics, University of Washington, Seattle, WA, USA.
Harrington KH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gudgeon CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Rafii S; Department of Genetic Medicine, Weill Cornell Medical College, New York, NY, USA.
Meshinchi S; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Department of Pediatrics, University of Washington, Seattle, WA, USA.
Appelbaum FR; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Bernstein ID; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Department of Pediatrics, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2014 Oct; Vol. 28 (10), pp. 1969-77. Date of Electronic Publication: 2014 Mar 18.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Mutation*
Hematopoietic Stem Cells/*cytology
Leukemia, Myeloid, Acute/*genetics
Antigens, CD34/metabolism ; Cell Hypoxia ; Cell Separation ; Coculture Techniques ; Core Binding Factors/metabolism ; Flow Cytometry ; Hematopoietic System ; Humans ; Leukemia, Myeloid, Acute/metabolism ; Prognosis ; Receptors, Aryl Hydrocarbon/metabolism ; Sialic Acid Binding Ig-like Lectin 3/metabolism
Czasopismo naukowe
Tytuł:
Molecular therapeutic approaches for pediatric acute myeloid leukemia.
Autorzy:
Tasian SK; Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania , Philadelphia, PA , USA.
Pollard JA; Division of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington , Seattle, WA , USA.
Aplenc R; Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania , Philadelphia, PA , USA.
Pokaż więcej
Źródło:
Frontiers in oncology [Front Oncol] 2014 Mar 18; Vol. 4, pp. 55. Date of Electronic Publication: 2014 Mar 18 (Print Publication: 2014).
Typ publikacji:
Journal Article; Review
Czasopismo naukowe
Tytuł:
The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.
Autorzy:
Ho PA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington; Children's Oncology Group, Arcadia, California.
Alonzo TA
Gerbing RB
Kuhn J
Pollard JA
Hirsch B
Raimondi SC
Gamis AS
Meshinchi S
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2014 Jan; Vol. 61 (1), pp. 81-8. Date of Electronic Publication: 2013 Aug 16.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Expression Regulation, Leukemic*
Genes, Wilms Tumor*
Leukemia, Myeloid, Acute/*genetics
Polymorphism, Single Nucleotide/*genetics
Aminoglycosides/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Child ; Disease-Free Survival ; Female ; Gemtuzumab ; Genotype ; Humans ; Infant ; Infant, Newborn ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/mortality ; Male ; Prognosis ; Real-Time Polymerase Chain Reaction ; Reverse Transcriptase Polymerase Chain Reaction ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies